REFERENCES
- Piddock LJV. New quinolones and gram-positive bacte-ria. Antimicrob Agents Chemother 1994; 38: 163–169.
- Rubinstein E, Carbon C. The fluoroquinolones-reap-praisal. J Antimicrob Agents 1992; 1: 147–152.
- Morrissey I, Hoshino K, Sato K, et al. Mechanism of dif-ferential activities of ofloxacin enantiomers. Antimicrob Agents Chemother 1996; 40: 1775–1784.
- Cherubin CE, Stratton CW. Assessment of the bacterici-dal activity of sparfloxacin, ofloxacin, and other fluoro-quinolones compared with selected agents of proven efficacy against Listeria monocytogenes. Diagn Microbiol Infect Dis 1994; 20: 21–25.
- Yamane N, Jones RN, Frei R, Hoban DJ, Pignatari AC, Marco F. Levofloxacin in vitro activity: results of an interna-tional comparative study with ofloxacin and ciprofloxacin. J Chemother 1994; 6: 83–91.
- Avril JL, Couete I, Travert MF, Autuly F, Plessis P. Sensibilite aux quinolones des Salmonella isolees chez l' homme et l'animal. Pathol Biol Paris 1995; 43: 270–273.
- Zhang YY, Wang F, Zhang JD, Thou L. In vitro antibac-terial activity of levofloxacin. Drugs 1995; 49 (Suppl. 2): 274-275.
- Mor N, Vanderkolk J, Heifets L. Inhibition an bacterici-dal activities of levofloxacin against Mycobacterium tuberculo-sis in vitro and in human macrophages. Antimicrob Agents Chemother 1994; 38: 1161–1164.
- Klesel N, Geweniger KH, Koletzki P, et al. Chemotherapeutic activity of levofloxacin (HR 355, DR 3355) against systemic and localized infections in laboratory animals. J Antimicrob Chemother 1995; 35: 805–819.
- Portnoy DA. Innate immunity to a facultative intracellu-lar pathogen. Curr Opin Immunol 1992; 4: 20–24.
- Skogberg, K, Syrjanen J, Jahkola M, et al. Clinical pre-sentation and outcome of listeriosis in patients with and with-out immunosuppressive therapy. Clin Infect Dis 1992; 14: 815–821.
- Dunlap NE, Benjamin NH, Briles DE. The intracellular nature of salmonella infection during the early stages of mouse typhoid. In: Zwilling BS, Eisenstein TK, eds. Macrophage-pathogen-interactions. New York: Marcel Dekker, 1994: 303–312.
- Nichterlein T, Kretschmar M, Budeanu C, Bauer J, Linss W, Hof H. Bay Y 3118, a new quinolone derivative, rapidly eradicates Listeria monocytogenes from infected mice and L 929 cells. Antimicrob Agents Chemother 1994; 38: 1501–1506.
- Woods GL, Washington JA. Antibacterial susceptibility tests: Dilution and disk diffusion methods. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. Manual of Clinical Microbiology. Washington, DC: ASM Press 1995: 1327-1341.
- Peterson LR, Shanholtzer CJ. Tests for bactericidal effects of antimicrobial agents: technical performances and clinical relevance. Clin Microbiol Rev 1992; 5: 420–432.
- Michelet C, Avril JL, Arvieux C, Jaquelinet C, Vu N, Cartier F. Comparative activities of new fluoroquinolones, alone or in combination with amoxicillin, trimethoprim-sul-famethoxazole, or rifampicin, against intracellular Listeria monocytogenes. Antimicrob Agents Chemother 1997; 41: 60–65.
- Garcia I, Pascual A, Conejo MC, Perea EJ. Intracellular penetration of 5 quinolones into non-phagocytic cells. Enferm Infec Microbiol Clin 1996; 14: 167–170.
- Jones EM, MacGowan AP. Antimicrobial chemotherapy of human infection due to Listeria monocytogenes. Eur J Clin Microbiol Infect Dis 1995; 14: 165–175.
- Hof H, Nichterlein T, Kretschmar M. Management of listeriosis. Clin Microbiol Rev 1997; 10: 345–357.
- McLaughlin J, Audurier A, Taylor AG. Treatment failure of recurrent human listeriosis. J Antimicrob Chemother 1991; 27: 851–857.